AV 101

Drug Profile

AV 101

Alternative Names: 4-Chlorokynurenine - VistaGen; 4-CL-KYN; 7-Cl-KYNA; AV-101; L-4-chlorokynurenine; L-4-CI-KYN

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator Artemis Neuroscience
  • Developer National Institute of Mental Health; VistaGen Therapeutics
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Antiparkinsonians; Neuroprotectants; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Phase I Epilepsy; Neuropathic pain; Parkinson's disease
  • Research Huntington's disease; Neurological disorders

Most Recent Events

  • 27 Apr 2017 Pharmacodynamics data from a preclinical trial in Neuropathic pain released by VistaGen Therapeutics
  • 29 Mar 2017 VistaGen Therapeutics receives notice of intention to grant patent for AV 101 in European union
  • 13 Feb 2017 VistaGen plans to initiate a phase IIb trial of AV 101 for Major depressive disorder (Adjunctive treatment) in USA, in the second quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top